Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis

NCT03167957 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped No longer target indication

Conditions

Vulvovaginal Candidiases
Yeast Infection
Vulvovaginitis
Yeast Infection Vaginal
Candidiasis, Vulvovaginal

Interventions

DRUG: Oral Encochleated Amphotericin B (CAMB)
DRUG: Oral Encochleated Amphotericin B (CAMB)

Sponsor

Matinas BioPharma Nanotechnologies, Inc.